Patients with a cancer of the lining of the lung, known as malignant pleural mesothelioma (MPM), lived longer than previously reported(ane), when treated amongst Eli Lilly as well as Company'sec Alimta(®) (pemetrexed) in combination with cisplatin, according to updated data presented at the 11th annual Conference on Lung Cancer (WCLC).
Mature information presented at WCLC correspond an update from lawsuit results from the largest randomized, Phase III mesothelioma trial always reported involving 448 patients published inward the Journal of Clinical Oncology (JCO) in July 2003(ii). This data showed median survival of patients treated alongside Alimta addition cisplatin was nigh xiii (12.viii) months afterward diagnosis as well as 42 per centum (3.8 months) longer than patients who received cisplatin solitary (p = 0.003).
Mature information presented at WCLC correspond an update from lawsuit results from the largest randomized, Phase III mesothelioma trial always reported involving 448 patients published inward the Journal of Clinical Oncology (JCO) in July 2003(ii). This data showed median survival of patients treated alongside Alimta addition cisplatin was nigh xiii (12.viii) months afterward diagnosis as well as 42 per centum (3.8 months) longer than patients who received cisplatin solitary (p = 0.003).
Advertisement
